

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Inventor(s): HANNA et al.

Appln. No.: 09

Series Code ↑

612,914

Serial No. ↑

Group Art Unit 1642

Examiner: Christopher Yaen

Atty. Dkt. P 0275543 037003

M#

Client Ref

Appln. Title: RECOMBINANT ANTI-CD4
ANTIBODIES FOR HUMAN THERAPY

Filed: July 10, 2000
 Mail Stop Non-Fee Amendment
 Hon. Commissioner for Patents
 PO Box 1450
 Alexandria, VA 22313-1450

Sir:

REPLY/AMENDMENT/LETTERDate: July 11, 2003
TECH CENTER 1600/2900

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim	For B & C See Required <u>Separate Paper</u> (Pat-256)	
A. <input checked="" type="checkbox"/> NOT made		
B. <input type="checkbox"/> Withdrawn		
C. <input type="checkbox"/> made herewith		

Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims	**minus 20	0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims	***minus 0	0	x \$84/\$42 =	+ \$0	102/202
4. If amendment enters <u>proper</u> multiple dependent claim(s) into this application for <u>first</u> time (leave blank if this is a reissue application)	add	+ \$280/\$140 =	+ \$0		104/204
5. Original due Date: July 11, 2003	<input type="checkbox"/> NONE				
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached	(1 mo) (2 mos) (3 mos) (4 mos) (5 mos)	\$110/\$55 = \$410/\$205 = \$930/\$465 = \$1,450/\$725 = \$1,970/\$985 =	+ \$110		115/215 116/216 117/217 118/218 128/228
7. Enter any previous extension fee paid since above original due date and subtract		- \$0			
8.		Extension Fee	+ \$110		
9. If Terminal Disclaimer attached, add Rule 20(d) official fee		+ \$110/\$55	+ \$110		148/248
10. If IDS attached requires Official Fee under Rule 97 (c), or if Rule 97(d) Request	add	+ \$180	+ \$0		126
	add	+ \$180			126
11. After-Final Request Fee per rules 129(a) and 17(r)		+ \$750/370	+ \$0		146/246
12. No. of additional inventions for examination per Rule 129(b)		x \$750/375 ea	+ \$0		149/249
13. Request for Continued Examination (RCE)		+ \$750/375	+ \$0		1179/1279
14. Petition fee for			+ \$0		
15.		TOTAL FEE =	\$220		

16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

Our Deposit Account No. 03-3975)

(Our Order No. 037003 0275543

C# M#

PLEASE CHARGE
OUR DEP. ACCT

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.


This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP
Intellectual Property Group

By Atty: Thomas A. Cawley, Jr., Ph.D.

Reg. No. 40944

Sig: Fax: (703) 905-2500
Tel: (703) 905-2144

Atty/Sec: TACJ/JB:ntb

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments



Reply Pursuant to 37 C.R.C.S. § 116
Expedited Proceedings
Group Art Unit 1641

RECEIVED
JUL 16 2003
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Nabil HANNA *et al.*

Group Art Unit: 1642

Application Serial No. 09/612,914

Examiner: Christopher Yaen

Filed: July 10, 2000

Title: RECOMBINANT ANTI-CD4 ANTIBODIES FOR HUMAN THERAPY

* * * * *

REQUEST FOR RECONSIDERATION

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is in response to the official action [final rejection] dated March 11, 2003, wherein the claims were rejected under 35 U.S.C § 112, second paragraph and the doctrine of obviousness-type double patenting.

09612914
033975
110.00 DA
01 FC:1251
07/15/2003 WABDELR1 000000094 033975